Immune Support

VIP

Vasoactive Intestinal Peptide

Neuropeptide regulating inflammation, vasodilation, and gut function

Research Status: Active clinical research; approved inhaled form for PAH (Aviptadil) Vasoactive Intestinal Polypeptide PHM-27 precursor
Mechanism of Action

How it works

VIP acts through VPAC1 and VPAC2 receptors to produce broad anti-inflammatory effects, smooth muscle relaxation, and vasodilation. It is a master regulator of Th2 immune responses and promotes regulatory T-cell differentiation.

Areas of Research

What the research explores

In published research, VIP has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.

  • Potent anti-inflammatory via Th2 immune shift
  • Vasodilation and pulmonary arterial hypertension research
  • Regulates gut motility and function
  • Neuroprotective and promotes neuronal survival
  • Studied for Long COVID and mast cell activation syndrome (MCAS)
  • Promotes regulatory T-cell differentiation
Research Highlight

Inhaled VIP (Aviptadil) reached Phase III trials for COVID-19 respiratory failure, showing significant improvement in survival in critically ill patients, and is FDA-approved for pulmonary arterial hypertension.

Safety Profile

Adverse events & gaps

Well-characterized. Transient flushing and hypotension due to vasodilation. Favorable overall profile.



Stay Informed on
Peptide Research

Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.

No spam. Unsubscribe at any time.